Reading view
Legal implications of AI standard of care integration on patients’ informed consent: lessons from surgery
npj Digital Medicine, Published online: 13 December 2025; doi:10.1038/s41746-025-02157-1
Legal implications of AI standard of care integration on patients’ informed consent: lessons from surgeryAI in 2026: Experimental AI concludes as autonomous systems rise
Generative AI’s experimental phase is concluding, making way for truly autonomous systems in 2026 that act rather than merely summarise.
2026 will lose the focus on model parameters and be about agency, energy efficiency, and the ability to navigate complex industrial environments. The next twelve months represent a departure from chatbots toward autonomous systems executing workflows with minimal oversight; forcing organisations to rethink infrastructure, governance, and talent management.
Autonomous AI systems take the wheel
Hanen Garcia, Chief Architect for Telecommunications at Red Hat, argues that while 2025 was defined by experimentation, the coming year marks a “decisive pivot towards agentic AI, autonomous software entities capable of reasoning, planning, and executing complex workflows without constant human intervention.”
Telecoms and heavy industry are the proving grounds. Garcia points to a trajectory toward autonomous network operations (ANO), moving beyond simple automation to self-configuring and self-healing systems. The business goal is to reverse commoditisation by “prioritising intelligence over pure infrastructure” and reduce operating expenditures.
Technologically, service providers are deploying multiagent systems (MAS). Rather than relying on a single model, these allow distinct agents to collaborate on multi-step tasks, handling complex interactions autonomously. However, increased autonomy introduces new threats.
Emmet King, Founding Partner of J12 Ventures, warns that “as AI agents gain the ability to autonomously execute tasks, hidden instructions embedded in images and workflows become potential attack vectors.” Security priorities must therefore shift from endpoint protection to “governing and auditing autonomous AI actions.”
As organisations scale these autonomous AI workloads, they hit a physical wall: power.
King argues energy availability, rather than model access, will determine which startups scale. “Compute scarcity is now a function of grid capacity,” King states, suggesting energy policy will become the de facto AI policy in Europe.
KPIs must adapt. Sergio Gago, CTO at Cloudera, predicts enterprises will prioritise energy efficiency as a primary metric. “The new competitive edge won’t come from the largest models, but from the most intelligent, efficient use of resources.”
Horizontal copilots lacking domain expertise or proprietary data will fail ROI tests as buyers measure real productivity. The “clearest enterprise ROI” will emerge from manufacturing, logistics, and advanced engineering—sectors where AI integrates into high-value workflows rather than consumer-facing interfaces.
AI ends the static app in 2026
Software consumption is changing too. Chris Royles, Field CTO for EMEA at Cloudera, suggests the traditional concept of an “app” is becoming fluid. “In 2026, AI will start to radically change the way we think about apps, how they function and how they’re built.”
Users will soon request temporary modules generated by code and a prompt, effectively replacing dedicated applications. “Once that function has served its purpose, it closes,” Royles explains, noting these “disposable” apps can be built and rebuilt in seconds.
Rigorous governance is required here; organisations need visibility into the reasoning processes used to create these modules to ensure errors are corrected safely.
Data storage faces a similar reckoning, especially as AI becomes more autonomous. Wim Stoop, Director of Product Marketing at Cloudera, believes the era of “digital hoarding” is ending as storage capacity hits its limit.
“AI-generated data will become disposable, created and refreshed on demand rather than stored indefinitely,” Stoop predicts. Verified, human-generated data will rise in value while synthetic content is discarded.
Specialist AI governance agents will pick up the slack. These “digital colleagues” will continuously monitor and secure data, allowing humans to “govern the governance” rather than enforcing individual rules. For example, a security agent could automatically adjust access permissions as new data enters the environment without human intervention.
Sovereignty and the human element
Sovereignty remains a pressing concern for European IT. Red Hat’s survey data indicates 92 percent of IT and AI leaders in EMEA view enterprise open-source software as vital for achieving sovereignty. Providers will leverage existing data centre footprints to offer sovereign AI solutions, ensuring data remains within specific jurisdictions to meet compliance demands.
Emmet King, Founding Partner of J12 Ventures, adds that competitive advantage is moving from owning models to “controlling training pipelines and energy supply,” with open-source advancements allowing more actors to run frontier-scale workloads.
Workforce integration is becoming personal. Nick Blasi, Co-Founder of Personos, argues tools ignoring human nuance – tone, temperament, and personality – will soon feel obsolete. By 2026, Blasi predicts “half of workplace conflict will be flagged by AI before managers know it exists.”
These systems will focus on “communication, influence, trust, motivation, and conflict resolution,” Blasi suggests, adding that personality science will become the “operating system” for the next generation of autonomous AI, offering grounded understanding of human individuality rather than generic recommendations.
The era of the “thin wrapper” is over. Buyers are now measuring real productivity, exposing tools built on hype rather than proprietary data. For the enterprise, competitive advantage will no longer come from renting access to a model, but from controlling the training pipelines and energy supply that power it.
See also: BBVA embeds AI into banking workflows using ChatGPT Enterprise

Want to learn more about AI and big data from industry leaders? Check out AI & Big Data Expo taking place in Amsterdam, California, and London. The comprehensive event is part of TechEx and is co-located with other leading technology events. Click here for more information.
AI News is powered by TechForge Media. Explore other upcoming enterprise technology events and webinars here.
The post AI in 2026: Experimental AI concludes as autonomous systems rise appeared first on AI News.
China leads research in 90% of crucial technologies — a dramatic shift this century
Nature, Published online: 12 December 2025; doi:10.1038/d41586-025-04048-7
The United States tops the remaining areas in an assessment of 74 technologies.Mapping the inflammatory origins of lung cancer
Cancer Cell. 2025 Dec 11:S1535-6108(25)00498-2. doi: 10.1016/j.ccell.2025.11.005. Online ahead of print.
ABSTRACT
How early precursor cells and their surrounding microenvironment cooperate to drive oncogenic progression in lung adenocarcinoma (LUAD) remains elusive. In this issue of Cancer Cell, Peng et al. conducted multimodal spatial-omics to comprehensively profile precancerous lung and LUAD tissues, uncovering alveolar progenitors and proinflammatory niches that co-evolve during cancer progression.
PMID:41386222 | DOI:10.1016/j.ccell.2025.11.005
Application progress of spatial omics in hepatobiliary tumor research
Hepatobiliary Surg Nutr. 2025 Dec 1;14(6):1028-1030. doi: 10.21037/hbsn-2025-aw-862. Epub 2025 Nov 25.
NO ABSTRACT
PMID:41383666 | PMC:PMC12690317 | DOI:10.21037/hbsn-2025-aw-862
Exploring the role of lipid metabolism genes in gastric cancer prognosis and tumor immune microenvironment
J Int Med Res. 2025 Dec;53(12):3000605251403252. doi: 10.1177/03000605251403252. Epub 2025 Dec 11.
ABSTRACT
BackgroundGastric cancer remains a major global health challenge due to its high mortality rate and complex pathophysiological mechanisms. Emerging evidence highlights that dysregulated lipid metabolism contributes to gastric cancer progression and prognosis, but the associations between lipid metabolism-associated genes, gastric cancer patient survival, and tumor immune microenvironment remodeling are not fully elucidated.MethodsWe analyzed publicly available omics and clinical data, including RNA sequencing data from 371 gastric cancer samples in The Cancer Genome Atlas database and 433 gastric cancer samples in the Gene Expression Omnibus database. We first curated the top 100 lipid metabolism-associated genes based on relevance scores. Then, univariate Cox regression was used to identify genes significantly associated with overall survival. Consensus clustering was applied to these survival-related genes to define gastric cancer molecular subtypes. Copy number variation analysis was performed to assess genomic alterations of these genes in tumor samples. A prognostic risk model was constructed using least absolute shrinkage and selection operator regression and validated via multivariate Cox regression. Immune infiltration analysis using CIBERSORT and ESTIMATE algorithms was conducted to explore associations between lipid metabolism-associated genes and tumor immune microenvironment characteristics.ResultsA total of 3911 differentially expressed genes were identified between gastric cancer and adjacent normal tissues. Among the top 100 lipid metabolism-associated genes, 43 were significantly linked to patient survival, most of which were considered as poor prognostic factors. Copy number variation analysis revealed frequent copy number gains of these genes in tumor samples. Consensus clustering stratified patients into two molecular subtypes (LMAGcluster A and LMAGcluster B), with LMAGcluster A showing significantly worse survival outcomes (median survival: 2.6 years vs. 8.3 years in LMAGcluster B, p < 0.001). LMAGcluster A was also characterized by elevated infiltration of pro-tumor immune cells, such as regulatory T cells and follicular helper T cells. The prognostic model based on 14 key lipid metabolism-associated genes exhibited robust predictive performance, with area under the receiver operating characteristic curve values of 0.702-0.761 in The Cancer Genome Atlas cohort and 0.621-0.638 in the Gene Expression Omnibus cohort for 1-, 3-, and 5-year survival.ConclusionLipid metabolism-associated genes are closely associated with gastric cancer prognosis and tumor immune microenvironment remodeling. The identified gene-based molecular subtypes and prognostic model provide novel insights into gastric cancer progression, and the 14 key genes may serve as potential biomarkers and therapeutic targets.
PMID:41381057 | DOI:10.1177/03000605251403252
Trump’s AI executive order promises ‘one rulebook’ — startups may get legal limbo instead
Minimal Residual Disease Detection: Bridging Molecular and Clinical Strategies for Recurrence Prevention in Gynecologic Cancers
Int J Mol Sci. 2025 Dec 3;26(23):11708. doi: 10.3390/ijms262311708.
ABSTRACT
Gynecologic cancers remain a major global health burden, particularly in low- and middle-income countries, with high incidence and mortality rates around 45-50%. The detection of minimal residual disease (MRD) is transforming the management of recurrence risk in gynecologic cancers through highly sensitive molecular technologies. MRD encompasses small populations of residual cancer cells or post-treatment molecular traces but remain undetectable by conventional methods. Its detection relies on circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and advanced next-generation sequencing (NGS), with ctDNA-based MRD assays having sensitivity levels between 85% and over 99%. Other technologies, such as liquid biopsies and digital PCR, are also in development. MRD status has demonstrated high predictors of recurrence and survival with positive MRD strongly associated with poor outcomes and negative MRD indicates sustained remission. However, MRD detection faces significant limitations, such as tumor heterogeneity, inconstant ctDNA levels, technical issues of false-negative results, and limited clinical accessibility. Therefore, this review presents current evidence regarding the molecular detection of MRD in gynecologic malignancies and assesses its prognostic and predictive relevance. Ultimately, MRD continuous integration into clinical practice offers a promising modality to enable early relapse detection, more precise therapeutic decision-making, and the improvement of personalized medicine access to gynecologic cancers worldwide.
PMID:41373852 | PMC:PMC12692091 | DOI:10.3390/ijms262311708
Exploring Health Misinformation Detection with Multi-Agent Debate
Mind the Gap! Pathways Towards Unifying AI Safety and Ethics Research
Robust AI Security and Alignment: A Sisyphean Endeavor?
Phythesis: Physics-Guided Evolutionary Scene Synthesis for Energy-Efficient Data Center Design via LLMs
IoTEdu: Access Control, Detection, and Automatic Incident Response in Academic IoT Networks
MedXAI: A Retrieval-Augmented and Self-Verifying Framework for Knowledge-Guided Medical Image Analysis
Are ultrasensitive ctDNA assays ready for clinical use in early-stage NSCLC?
Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy
D2M: A Decentralized, Privacy-Preserving, Incentive-Compatible Data Marketplace for Collaborative Learning
Pancreatic Cancer Organoids: Modeling Disease and Guiding Therapy
Cancers (Basel). 2025 Nov 30;17(23):3850. doi: 10.3390/cancers17233850.
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. An unmet need exists for reliable biomarkers and in vitro models capable of predicting patient drug response to advance personalized medicine. Traditional models fail to represent the tumor's complexity and the role of the stromal environment in chemoresistance. Patient-derived organoids (PDOs) overcome these limitations, enabling multi-omics profiling and reliable drug testing for functional precision medicine. This review provides a comprehensive overview of PDAC PDO research, emphasizing the following major areas: (i) the genetic and phenotypic fidelity of PDOs, (ii) their predictive value for drug response and chemoresistance, (iii) the integration of the extracellular matrix and tumor microenvironment (TME) components, and (iv) emerging technologies. Studies confirm that PDOs faithfully represent the primary tumor's specific genetic features and retain intratumoral heterogeneity. PDO-based platforms have demonstrated a strong correlation between in vitro drug sensitivity and in vivo efficacy in xenograft models, validating their utility for identifying drug candidates, repurposing existing drugs, and determining effective combinations. Efforts are ongoing to integrate crucial TME components, like cancer-associated fibroblasts, using innovative co-culture platforms such as fused PDOs and InterOMaX, to better model desmoplasia and chemoresistance mechanisms. Furthermore, PDO technology is converging with microphysiological systems and artificial intelligence tools to facilitate high-throughput drug screening and dynamic, real-time monitoring of therapeutic effects. The integration of PDOs into biobanks and advanced screening platforms holds the potential to accelerate drug discovery and improve therapeutic outcomes for PDAC patients, if challenges related to protocol standardization and regulatory acceptance are addressed.
PMID:41375051 | PMC:PMC12690986 | DOI:10.3390/cancers17233850